Overview
Neurofilament Light Chain Protein (NfL) has been found by many studies as a sensitive biomarker of neuronal damage from several reasons, e.g. neurodegenerative diseases (Alzheimer's disease, Multiple Sclerosis, etc.), inflamation (HIV) or trauma. Its role as biomarker thus offers a possibility to predict and manage diseases associated with neuronal damage. Therefore our aim is to investigate the changes in level of NfL in hydrocephalus and to find its role in management of treatment in hydrocephalus.
Eligibility
Inclusion Criteria:
- In group A:
- Patients with diagnosed communicating hydrocephalus
- MMSE > 10 points
- Absence of any structural laesion on MRI or CT
- Accepted Informed consent
- In group B:
- MMSE > 10 points
- Absence of any structural laesion on MRI or CT
- Accepted Informed consent
- Elective spinal surgery without affecting dural sac and the spinal cord
- Surgery shorter than 120 minutes of lasting the general anesthesia
Exclusion Criteria:
- Non-communicating hydrocephalus
- Structural laesion on MRI or CT (tumour, contusion, aneurysm)
- MMSE < 10 points
- Life-expectancy shorter than 1 year
- Pre-existing other type of demetia (m. Alzheimer, vascular dementia)
- Surgery lasting more than 120 minutes
- Blood loss more than 500 ml
- Opening of dural sac (liquororhea)
- Adverse events during general anestesia: MAP<60 mm Hg more than 5 minutes, arythmia with need for farmacological treatment